Ranking Invest

DCPH - Deciphera Pharmaceuticals, Inc.

Segmento: HealthcareDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 500.58 Mi
Valor de Mercado
$ 2.21 Bi
Desconto (AV)-542.1%
MLL
-0.37A companhia gerou lucro líquido equivalente a -37% do seu valor de mercado nos últimos 4 trimestres.
Último Balanço Atualizado: 1T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 316.05 Mi

Dívida Líquida

-$ 66.20 Mi

L4T

-$ 190.42 Mi

MM4T

-109.79%

Indicadores Básicos

ROE

-60.25%

Índices de Previsibilidade

Faturamento

0.09

Lucro

0.14

Margem

0.25

Índices de Tendência

Faturamento

11.47

Lucro

7.43

Margem

10.80

Índices de Endividamento

DIV/PAT

-0.21

DIV/L4T

0.35

Dívidas
Cotação
Gráfico Lucro/Faturamento X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.